#CureSMA2021 – Evrysdi Shows Promise as Secondary Therapy

#CureSMA2021 – Evrysdi Shows Promise as Secondary Therapy

296361

#CureSMA2021 – Evrysdi Shows Promise as Secondary Therapy

Editor’s note: The SMA News Today team is providing in-depth coverage of the 2021 Virtual SMA Research & Clinical Care Meeting, held June 9–11. Go here to read stories from the conference.  Evrysdi (risdiplam) appeared both safe and effective when used after other therapies to treat five patients with spinal muscular atrophy (SMA), a small study showed. The results suggest that this therapeutic approach — of using Evrysdi as a second-line or secondary treatment —…

You must be logged in to read/download the full post.